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Abstract: Since the advent of phage display technology, dating back to 1985, antibody 
libraries  displayed  on  filamentous  phage  surfaces  have  been  used  to  identify  specific 
binders for many different purposes, including the recognition of tumors. Phage display 
represents a high-throughput technique for screening billions of random fusion antibodies 
against virtually any target on the surface or inside cancer cells, or even soluble markers 
found in patient serum. Many phage display derived binders targeting important tumor 
markers  have  been  identified.  Selection  directed  to  tumoral  cells’  surfaces  lead  to  the 
identification of unknown tumoral markers. Also the improvement of methods that require 
smaller amounts of cells has opened the possibility to use this approach on patient samples. 
Robust  techniques  combining  an  antibody  library  displayed  on  the  phage  surface  and 
protein microarray allowed the identification of auto antibodies recognized by patient sera. 
Many Ab molecules directly or indirectly targeting angiogenesis have been identified, and 
one of them, ramucirumab, has been tested in 27 phase I–III clinical trials in a broad array 
of cancers. Examples of such antibodies will be discussed here with emphasis on those 
used as probes for molecular imaging and other clinical trials. 
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1. Monoclonal Antibodies, Useful Diagnostic and Therapeutic Molecules 
Antibodies have been used for antigen detection and therapeutics, and their specificity combined 
with low toxicity make them a promising pharmaceutical commodity [1]. Actually, they comprise the 
second-largest category of biological medicines in clinical development, after vaccines [2]. Successful 
examples include rituximab, approved by the FDA since 1997, an anti-CD20 chimeric antibody that 
become an integral component of many treatment strategies for non-Hodgkin’s lymphoma [2], and 
OKT3, an anti-CD3 that is used to reduce graft rejection [3]. Therapeutic use of antibodies is limited by 
methodological constraints in raising them. They are commonly obtained by immunization of experimental 
animals,  usually  mouse,  with  target  antigens.  The  screening  leads  to  a  specific  antibody-producing 
hybridoma  [4].  Although  well  established,  this  technology  is  laborious,  and  it  is  biased  by  the 
experimental animal immune system, which limits the ability to reach a high-affinity antibody against 
conserved mammal proteins. Additionally, the heterologous character of those proteins turn them often 
immunogenic to humans eliciting HAMA response (Human Anti-Mouse Antibodies), which restrict 
their therapeutic use [5]. Human antibodies are of particular interest due to a lower immunogenicity 
response [1]. Antibody humanization bypasses this bottleneck, minimizing the HAMA response by 
replacing murine sequences with human framework homologous sequences [6]. The challenge is to 
avoid  immunogenicity  and  maintain  the  specificity.  Humanized  antibodies  are  a  reality  in  many 
diseases treatments nowadays, including cancer therapy and diagnosis. Some successful examples are 
Herceptin, used for breast cancer therapy; Avastin, used in clinics to treat colorectal cancer; Lucentis, 
an anti-VEGF antibody, among others. Antibodies proprieties are incontestable; nevertheless, some 
applications can be limited by their molecular size. They present poor penetration into tissues (e.g., 
solid tumors) and poor or absent binding to functionally important regions on the surface of some 
molecules by sterical constrains. Antibody fragments such as Fab (fragment antigen-binding), scFv 
(single-chain  variable  fragment)  are  alternatives  to  decrease  an  antibody’s  size  and  increase  its 
penetration into tissues. Therefore, several efforts have been employed to develop novel smaller sized 
scaffolds. Scaffolds derived from single antibody domains can be about 10-fold smaller than full size 
antibodies [7,8]. Single-domain antibodies (sdAbs or dAbs), molecules containing either heavy chain 
or  light  chain  variable  regions  of  human  antibodies,  and  nanobodies  derived  from  the  variable  
regions of HCAbs (heavy chain-only antibodies) of camelids [9], are the smallest antigen binding  
fragments tested. 
A  suitable  approach  to  obtain  human  antibodies  and  their  fragments  is  the  construction  and 
selection of human antibody combinatorial libraries displayed on filamentous phage surfaces [10]. 
These libraries can be synthetic or obtained from human patient repertoires and the selection of binders 
is performed targeting a previously defined ligand, resulting in a completely human antibody fragment, 
theoretically less immunogenic than murine or humanized ones. Antibody phage display indeed has 
generated numerous human recombinant antibodies for research, diagnostics and therapy. In 2003, the 
FDA approved the first phage display antibody, Adalimumab (Humira), to treat rheumatoid arthritis. 
Currently it is used also to treat psoriasis, arthritis, ankylosing spondylitis and Crohn’s disease, and 
clinical trials to expand its utilization to other diseases are under way [11]. Other examples, in Phase I 
or II clinical trials include human antibodies against HIV (a combination of three human antibodies: 
C2F5, C2G12 and C4E10; phases I and II, NCT00219986), GM-CSF (MT-203, Phase I, NCT01317797) Int. J. Mol. Sci. 2012, 13  5422 
 
and  CD20  (ofatumumab,  phase  II  for  treat  patients  that  are  rituximab refractory,  NCT00394836), 
tested for treatment of different diseases [12]. 
The purpose of this review is to depict the utilization of phage display libraries in selecting specific 
tools to be used in cancer research. Examples of Fab, scFv, sdAb or others antibody fragments derived 
from naï ve or immunized libraries will be addressed. Binders used on research, in preclinical analysis 
and  as  molecular  imaging  probes  will  be  illustrated.  Finally,  we  will  explore  clinical  trials  using 
antibodies obtained from phage display libraries. 
2. Antibody Phage Display Libraries 
Phage  display  was  established  by  George  P.  Smith  in  1985  and  describes  the  presentation  of 
exogenous peptides on the coat of phage particles. It is based on the observation that bacteriophages 
from  the  Inoviridae  family  (M3,  fd,  fl)  are  properly  packaged  and  retain  infectivity  even  in  the 
presence of foreign peptides fused to their capsid proteins [13]. A phage display library is obtained by 
genetic manipulation. Billions of peptides, protein variants, antibody fragment coding genes are cloned 
into a vector fused to the 5' of one of the filamentous bacteriophage coat protein (pIII or pVIII) genes. 
Those phagemid libraries are used to transform bacteria which will be also infected with the helper 
phage.  The  helper  phage  infection  allows  the  assembling  of  viral  particles  displaying  the  fusion 
proteins on their surface [14]. Since the coat protein provides only an anchor for the displayed peptide 
it  should  not  interfere  with  its  structure  and  allows  affinity  purification  of  the  peptide  and  its 
corresponding gene. This rational also applies for antibody fragments presentation on the surface of 
filamentous phage [10,15,16]. 
Different strategies can be employed to obtain an antibody combinatorial phage display library. 
There are some synthetic or semi-synthetic libraries, constructed based on human variable light (VL) 
and  variable  heavy  (VH)  repertoires.  The  most  used  ones  are  Griffin-1  library  (H  Griffin,  MRC, 
Cambridge, UK), composed by the majority of human VH and VL gene segments used in vivo, with 
additional CDR3 diversity generated using synthetic oligonucleotides (semi-synthetic) and Tomlinson 
I Library [17] that consists of a single human framework with diversity incorporated at 18 amino acid 
positions among VH and VL domains, mainly in the antigen binding site (synthetic). In both libraries 
the antibodies are displayed as scFvs. Several human antibodies were obtained from these libraries, 
used alone or in combination in biopanning processes [18,19]. Another strategy is the construction of a 
library obtained from amplifying the variable gene repertoires of one or more individuals. For this aim, 
primers covering all V gene families are used and the library is generated by a random combination of 
VL and VH chain coding genes. Again, the antibody coding genes are assembled to be displayed as 
Fab or scFv antibody fragments [5]. Theoretically, each clone codes for a specific antigen-binding site, 
derived  from  the  natural  repertoire  which  is  increased  by  an  artificial  domain  shuffling  that 
extrapolates the original repertoire.  
The panning procedure mimics the B-cell clonal selection system in vitro by specifically enriching 
phage particles that display antibodies with a desired specificity [15]. During library construction it is 
important to assure library diversification, thus the size of the library is pivotal for attempting efficacy 
in selecting binding forms for any given antigen. Combinatorial antibody libraries can be constructed 
from a repertoire of immunized [20–22] or non immunized donors [20–22]. Even in the last case, Int. J. Mol. Sci. 2012, 13  5423 
 
selection provides high-affinity antibodies [23] against different types of antigen: haptens, proteins, 
peptides and carbohydrates. 
Most  of  the  panning  methods  are  based  on  four  major  steps:  preparation  of  phage-displayed 
libraries, adsorbing the specific binding phage, removal of nonspecific or low affinity phages, and 
recovering of target binders, that will be reamplified after bacteria infection for the next round of 
selection  [24].  The  selection  procedure  results  in  the  sequential  enrichment  of  phages  displaying 
specific binding to a chosen pure or impure antigen (Figure 1). These panning steps will be repeated, 
usually 3 to 5 times, until the identification of high specific/affinity binder [25,26]. Commonly, a 
purified antigen is immobilized into a support like resin or beads. More complex systems such as 
eukaryotic cells and tissue fragments can be used and even in vivo panning has been reported. The 
utilization of a phage display library to target organs in vivo was first described by Pasqualini and 
Ruoslahti, in 1996 [27]. Automated phage display screening for high throughput antibody development, 
which increase reproducibility of the selection protocol, has been developed [28]. 
Figure 1. General scheme of phage display technology. (A) Generation of a phage display 
library by mRNA extraction, cDNA cloning into a phagemid vector and phage propagation; 
(B) Biopanning: affinity against tumoral cells driven enrichment of target specific binders 
during several rounds of selection. 
 
Selecting  phages  on  the  cell  surface  is  an  important  step  toward  the  development  of  targeted 
therapeutics  for  cancer;  it  opens  the  opportunity  to  obtain  antibodies  against  unknown  and  
non-immunogenic  cell  surface  antigens  in  their  native  form.  As  the  target  antigen  becomes  more 
complex, such as cell surface, the selection procedure becomes more difficult. The cell membrane Int. J. Mol. Sci. 2012, 13  5424 
 
presents a myriad of proteins, carbohydrates and lipids as potential antigens. Their expression level can 
differ from cell to cell, which renders the presence of a relevant antigen to a minute amount among all 
the cell membrane components. As a consequence, a relatively large number of cells (10
5–10
7) is 
required for each round of selection, making the application of this technique difficult for small cell 
populations such as usually is obtained from organs and tissues. Efforts have been made to improve 
selection on the cell surface, once panning methods are based on extensive washes, turning them 
laborious, cell consuming and often inefficient, yielding variable results [29]. More efficient methods 
have been proposed, which includes centrifugation on density gradient or on organic phase instead of  
washing  [29,30].  Recently  a  new  cell-surface  biopanning  method  based  on  the  microfluidics 
technology  was  proposed.  The  accurate  control  of  washing  stringency  in  the  microfluidic  
magnetic  separator  (MMS)  circumvents  cell  loss  and  allows  efficient  removal  of  weakly  or  
nonspecifically-bound  phages  [31].  The  small  numbers  of  cells  required  constitutes  an  advantage, 
rendering MMS a promising tool for the discovery of biomarkers from patient samples. 
The phage display library approach has been extended to other alternatives including ribosomal [32] 
yeast [33], mammalian systems [34] or eukaryotic viruses [35], which have been extensively discussed 
elsewhere [36,37] and are not the objective of this review. A strategy called protein scaffolds proposes 
to engineer non-immunoglobulin proteins by the incorporation of a customized affinity domain [38].  
It represents an alternative to antibodies for molecular recognition and is presented as libraries in 
phage display-scaffolds [38,39]. This is beyond the scope of this review since we will concentrate on 
the antibody phage display systems. 
2.1. Immunized Phage Display Libraries 
The construction of a phage display library using the entire antibody genes repertoire of a cancer 
patient followed by controlled panning procedure allows the identification of rare antibodies based on 
their binding specificities [15]. The utilization of immune libraries to detect tumoral cells antigens 
demonstrates  the  occurrence  of  an  immunodominance  phenomenon  in  certain  cancers  [40].  The 
immunodominance corresponds to the presence of a dominant antigen recognized for the majority of 
the  immune  response  components.  If  an  immunodominance  phenomenon  occurs,  the  diversity  of 
selected clones harboring specific antibodies will be limited. The specificity of the majority population 
of isolated antibodies will be determined by the antigenic profile of the cells used. From melanoma 
patients there are two examples of limited selected antibodies using antibody libraries from patients.  
A fusion scFv phage library expressing the antibody repertoire of two melanoma patients immunized 
with  cultured  autologous  tumor  cells,  transduced  with  the  γ-interferon  gene  to  enhance 
immunogenicity was constructed [41]. A Fab library also from melanoma patients was constructed by 
Pereira  et  al.  [42].  From  both  libraries,  only  one  specific  clone  was  selected,  suggesting  that  an 
immunodominant epitope may exist in melanoma cells. Immunodominance seems to occurs also in 
osteosarcoma, in  a previous  work we  constructed a  Fab phage display library from osteosarcoma 
patients, after selection on osteosarcoma cell lines we were able to isolate 5 tumor associated Fabs; 
despite sharing different VH and VL sequences, they recognize the same over expressed protein in the 
osteosarcoma cells and tissue [43]. Other examples include the selection of antibodies against anti-FBP 
a protein highly expressed in ovarian carcinoma [44], anti-melanoma and breast cancer [45]. Int. J. Mol. Sci. 2012, 13  5425 
 
The serological identification of Ags by recombinant cDNA expression cloning (SEREX) method 
was  designed  to  exploit  patient  serum  to  probe  a  tumor  specific  cDNA  expression  library  with 
autologous  patient  serum  (serological  cDNA  screening).  SEREX  allowed  the  identification  of 
immunogenic tumor proteins in many tumor types [46,47]. Nevertheless, this method is laborious and 
the  nonquantitative  format  of  the  secondary  screening  assay  on  an  individual  serum  hampers  the 
analysis of large panels of candidate antigens against hundreds of serum samples of limited amounts. 
To  circumvent  this  problem,  another  method  allying  SEREX  to  phage  display  technology  was 
developed and called SAS (serological Ag selection). This procedure uses repeated cycles of selection 
and amplification of phage cDNA libraries on patient serum to enrich immunoreactive cDNA products 
displayed  on  the  phage  surface  [48].  The  SAS  method  allowed  the  identification  of  a  panel  of 
candidate  tumor  antigens  in  colorectal  cancer  [49].  Further,  a  robust  approach  combining  phage 
display  library  derived  from  cancer  tissue  with  protein  microarray  was  proposed  by  
Fernandez-Madrid et al. [50]. At first, a phage display cDNA library from breast cancer samples was 
screened against sera from 10 patients, then a microarray of the positive phages was probed with sera 
from another 90 patients. The selected autoantigens could significantly discriminate between breast 
cancer  and  non-cancer  control  sera.  A  similar  approach  has  been  used  to  characterize  new 
autoantibody-binding  peptides  derived  from  a  prostate-cancer  tissue  phage  library.  A  panel  of  
22 potentially diagnostic markers, contained, among others, eIF4G1, a protein that is over expressed in 
prostate-cancer epithelial tissue [51]. Again a combination of phage display with high-density peptide 
microarray was used to detect the autoantibodies in the sera from lung adenocarcinoma patients. The 
study led to the detection of a number of novel peptide targets that elicit a humoral immune response 
in lung cancer patients and can predict cancer status with 85% sensitivity and 86% specificity. Among 
the  identified  peptides  there  was  ubiquilin  1  (a  protein  that  regulates  the  degradation  of  several  
ubiquitin-dependent proteasome substrates), which is significantly increased in lung tumors [52]. These 
studies suggest that the humoral immune response may be useful in the diagnosis and classification of 
tumors and pave the way of the emerging area, termed ―cancer immunomics‖ [53] which constitutes 
the analysis of the host humoral immune response against tumoral cells. 
2.2. Immunized Animals as Source of Antibody Repertoire 
Immunized  animals  can  also  be  used  as  a  source  of  antibody  repertoire.  Potential  therapeutic 
antibodies were identified from a phage library displaying antibodies from rabbits immunized with 
primary chronic lymphocytic leukemia (CLL) cells [54]. A first generation of chimerical rabbit/human 
Fab and IgG1 that bind ROR1 with high affinity and specificity was generated from those immunized 
rabbits and selected by phage display. This work provides both rationale and platform for a second 
generation of mAbs and antibody derivatives [55]. A single-chain Fv antibody fragment specific for 
CD123 were isolated from a phage display library generated from mice spleen mRNA. The animals 
were immunized with a fusion protein consisting of the extracellular domain of CD123 and the Fc 
domain of a human immunoglobulin. The scFv with the highest affinity for leukemia stem cells (LSCs) 
in acute myeloid leukemia (AML) was used to design two cell death-inducing molecules. First, an 
immunotoxin, a fusion protein with truncated Pseudomonas Exotoxin A, induced potent apoptosis of 
AML-derived cells. Second, a bispecific single chain Fv (bsscFv) created by the fusion to another scFv Int. J. Mol. Sci. 2012, 13  5426 
 
specific for CD16, which mediated potent lysis of AML-derived cells inducing antibody-dependent 
cellular cytotoxicity (ADCC) reactions. The recruitment of CD16-positive effectors cells for the lysis 
of AML cells via CD123 opens a promising combination for future clinical testing [56]. 
Another molecule format, the sdAb, is a very useful component in antibody engineering as potential 
tools  for  diagnostic  and  therapeutic  application.  Baral  et  al.  [57]  have  isolated  an  sdAb  against 
CEACAM  6  from  a  llama  immunized  with  cancer  cells.  This  molecule  reduces  proliferation  on 
CEACAM expressing cells and shows excellent tumor targeting in vivo, thus presenting potential in 
diagnosis  and  therapy  of  CEACAM6  expressing  tumors.  Recently  Bell  et  al.  [58]  described  the 
isolation of eleven sdAbs from an imunized llama that target EGFR and the construction of pentabody 
(V2C-EG2) and cHCAb (EG2-hFc) versions of one of these sdAbs (EG2). These three versions of 
EG2  were  radiolabeled  with 
64Cu  and  microPET/CT  imaging  was  used  to  analyze  their  in  vivo 
distribution in a human pancreatic carcinoma xenograft model. Whereas EG2 and V2C-EG2 localized 
mainly in the kidneys after i.v. injection, EG2-hFc exhibited excellent tumor accumulation, and this 
was largely attributed to its long serum half-life, which is comparable to that of IgGs. The moderate 
size (~80 kDa) and intact human Fc make HCAbs a unique antibody format which may outperform 
whole IgGs as imaging and therapeutic reagents. 
These examples illustrate that, undoubtedly, phage display technologies have great potential for 
proteome-wide exploration of humoral immune response and for production of therapeutic antibodies, 
either from cancer immunized patients or animals. 
2.3. Nom-Immune Libraries to Identify Binders to Tumor Markers 
Phage display panning strategy using the universal non-immunized (naїve) libraries of scFv has 
been largely used to specifically identify binders against most important targets in oncology. Here we 
explore some interesting molecules obtained from naï ve antibody libraries against VEGF and HER2.  
Signal  transduction  through  the  vascular  endothelial  growth  factor  (VEGF)  and  its  receptor 
VEGFR-2/kinase  domain  receptor  (KDR)  plays  a  crucial  role  in  angiogenesis,  and  has  therefore 
become a major target for therapeutic applications [59]. Phage display has been largely exploited to 
select high affinity binders to VEGF. Different molecule formats have been proposed such as VH 
binders [60], disulfide-stabilized single chain antibody variable fragments (sc-dsFv) [61], anti-VEGF 
ccFv (Fab-like antibody binding unit in which a pair of heterodimeric coiled-coil domains was fused to 
VH and VL) antibody [62]. The specific interaction between VEGF and its receptors has been targeted 
by blocking agents such as Fab [63], peptide [64], or scFv targeting the VEGF165 isoform [65]. Phage 
display was even used against mutated forms of VEGF [66], or VEGF-C [67] and in vivo, to identify 
tumor-homing peptides that specifically target tumor blood vessels, with the potential to improve the 
systemic treatment of patients with solid tumors [68]. We must mention also the Ramucirumab, a 
monoclonal  antibody  derived  from  phage  display  that  is  used  in  clinical  trials,  and  will  be  
detailed later.  
Epidermal growth factor receptors (EGFRs) are overexpressed and/or dysregulated in many tumor 
types. The EGFR family contains four members: EGFR1 (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and 
HER4 (ErbB4) [69]. Human Epidermal Growth Factor Receptor-2 HER2 (erbB2, HER2/neu) is highly 
expressed in some breast cancers, ovarian and gastric cancers [70]. Since the discovery of its role in Int. J. Mol. Sci. 2012, 13  5427 
 
tumorigenesis,  HER2  has  been  largely  explored  as  a  tumoral  target  leading  to  the  successful 
development of the humanized monoclonal anti-HER2 antibody (Trastuzumab) used for breast cancer 
treatment. Phage display has contributed, especially in the identification of smaller molecules. A large 
number of HER2 specific binders for diagnostic and therapy have been proposed. Phage display has 
contributed  to  identification  of  HER2  antibodies  [71],  peptides  [72],  llama  anti-Id  single  domain 
antibody (sdAb), anti-HER2 [73] and human anti-Id scFv against trastuzumab [74]. 
3. Phage Display to Select Antibodies for Molecular Imaging 
Medical  imaging  technologies  have  become  a  crucial  tool  in  oncology.  Advances  provided  by 
genetics,  biochemistry,  immunology  and  cellular  biology  concerning  tumorigenesis  need  to  be 
exploited. Molecular probes are not limited to tumor location; they became an integral part of clinical 
trials allowing monitoring of individualized treatment and may help drug development. Usually the 
majority of such probes are obtained from peptides phage libraries once peptides present high affinity 
and selectivity, and are also  less immunogenic, showing  lower toxicity and exhibiting  predictable 
pharmacokinetic properties. Nevertheless, antibodies, mainly fragments, have also been utilized due to 
their intrinsic high affinity. 
It  is  not  surprisingly  that  the  majority  of  antibodies  selected  for  molecular  imaging  target 
angiogenesis.  Zehnder-Fjä llman  et  al.  [75]  selected  a  scFv  targeting  VEGFR-3.  The  clone  AFC5 
showed specific tumor accumulation in a hVEGFR-3 expressing F9 teratocarcinoma in a mouse model 
by combined single proton emission computed tomography (SPECT/CT) and immunohistochemical 
analysis. The antibody has also the ability to block the interaction of hVEGF-C to its receptor; thus, 
reducing proliferation of human lymphatic endothelial cells. Apart from VEGF/VEGFs, angiogenesis 
can  be  targeted  in  other  ways,  such  as  by  integrins  and  MMPs  and  even  to  fibronectin,  a  
high-molecular weight  glycoprotein  that binds  to  integrins  [76]. The oncofetal  fibronectin (B-FN) 
isoform is present in vessels of neoplastic tissues during angiogenesis but not in mature vessels. Phage 
display was used to isolate human antibody targeting this specific fibronectin isoform. The scFv (L19) 
was identified and has been shown to efficiently localize on neovasculature in vivo. Imaging in real 
time was done to study biodistribution of scFv L19 coupled chemically to a fluorophore by infrared 
photodetection in human teratocarcinoma bearing mice [77]. Later, the same L19 small immunoprotein 
(SIP)  was  labeled  by 
76Br  allowing  detailed  small-animal  PET  of  tumor  neovasculature  [78].  
124I-L19-SIP is also suitable for immuno-PET [79].  
To study the vascular endothelia, a phage-displayed antibody was converted into a single-chain 
variable  fragment  and  fused  to  the  crystallizing  fragment  of  an  antibody  (scFv-Fc).  Such  fusion 
proteins  are  able  to  rapidly  target  vascular  endothelia  of  specific  organs  in  vivo.  Radioiodinated  
scFv-Fcs homing to specific organs were observed in vivo imaged by planar scintigraphy [80]. Other 
examples  include  an  anti-c-Met  scFv  conjugated  quantum  that  reveals  higher  tumor  uptake  and 
increased tumor-normal tissue ratios by in vivo fluorescent imaging [81]. Those molecules are valuable 
tools to expand our understanding of tumorigenesis. Int. J. Mol. Sci. 2012, 13  5428 
 
4. Antibodies Derived from Phage Display Libraries Used in Clinical Trials 
The most successfully derived phage display antibodies proved their efficacy in pre-clinical studies 
and  are  currently  being  tested  in  clinical  trials  as  single  agents,  in  combination  regimens  or  as 
radiolabeled molecules for imaging. These results are presented in Table 1, and are detailed below. 
Table  1.  Examples  of  monoclonal  antibodies  derived  from  phage  display  technology 
currently under evaluation for cancer therapy in clinical trials. Phage display monoclonal 
antibodies used in clinical trials. 
Name  Target  Format  Phase  Indication 
1D09C3  HLA-DR  H IgG4   I  Hodgkin’s lymphoma, myeloma 
Lexatumumab  TRAIL-R2  H IgG1   I  Advanced solid tumors 
Moxetumomab 
pasudotox 
CD22  Recombinant 
immunotoxin 
I,II  Acute lymphoblastic leukemia , hairy cell 
leukemia, non-Hodgkin lymphoma 
Fresolimumab  TGFβ   H IgG4   I,II  Breast cancer; gliomas, kidney cancer; 
melanoma; mesothelioma.  
Cixutumumab  IGF1R   H IgG1   I,II  Adrenocortical carcinoma; breast cancer; 
colorectal cancer; HNC; islet cell cancer; liver 
cancer; Malignant Fibrous Histiocytoma 
neuroendocrine cancer; NSCLC; pancreatic 
cancer; prostate cancer; sarcoma; SCLC; solid 
tumors.  
Mapatumumab  TRAIL-R1  H IgG1   II  Advanced Cervical Cancer, Hepatocellular 
Carcinoma, Multiple Myeloma 
Necitumumab  EGFR  H IgG1   III  NSCLC 
Ramucirumab  VEGFR2   H IgG1   III  Hepatocellular carcinoma, metastatic gastric  
or gastresophageal junction adenocarcinoma  
4.1. 1D09C3 (GPC Biotech AG) 
1D09C3  is  an  anti-MHC  class  II  (HLA-DR)  fully  human  IgG4  antibody  directed  against  cell 
surface  antigens.  Antibodies  of  the  IgG4  subclass  present  the  advantage  of  poor  induction  of the 
complement system, and as a consequence have received great attention as therapeutic molecules. It is 
known that the major histocompatibility complex class II protein HLA-DR is highly expressed in 
various tumors, including T and B-cell lymphomas and in a variety of autoimmune and inflammatory 
diseases. 1D09C3 induces apoptosis in MHC-II positive cells [11]. A radiolabeled fully humanized 
IgG4  monoclonal  antibody  (mAb)  can  provide  a  useful  tool  for  prognostics  and  diagnostics.  
Malviya et al. [82] attested the efficacy of labeled 1D09C3 with technetium-99m to target HLA-DR 
antigens.  Successful  preclinical  results  in  lymphoma  [83]  and  myeloma,  in  combination  with  
γ-IFN [84] have been reported. 1D09C3 received the orphan drug designation for the treatment of 
Hodgkin’s  lymphoma  by  the  European  Medicines  Agency  (EMEA)  in  2005.  Nevertheless,  no 
conclusive result on phase I clinical trials are published so far. Int. J. Mol. Sci. 2012, 13  5429 
 
4.2. Fresolimumab (GC-1008—Cambridge Antibody Technology/Genzyme) 
Fresolimumab  is  a  human  IgG4  monoclonal  antibody  that  neutralizes  all  three  isoforms  of 
transforming growth factor-β. TGF-β is involved in a variety of cellular processes such as proliferation, 
differentiation, and migration and is overexpressed in many tumor cells. Suppression of TGF-β using 
antibodies, soluble receptors or inhibitors of TGF-β signal transduction has shown beneficial effects in 
murine tumor models. The G4 immunoglobulin (IgG4) subclass does not activate the complement 
pathway, a suitable characteristic for an antibody. Fresolimumab tumor uptake and organ distribution 
could  be  visualized  and  quantified  with  89Zr-fresolimumab  PET  in  tumor  
models [85]. This technique could be a valuable tool to identify patients who would benefit most from 
such an anti-cancer treatment. A phase II study to evaluate 89Zr-GC1008 PET uptake in malignant 
gliomas  (NCT01472731)  is  ongoing  along  with  a  clinical  trial  to  evaluate  fresolimumab  and 
radiotherapy in metastatic breast cancer (NCT01401062). 
4.3. Cixutumumab (IMC-A12—ImClone Systems Incorporated) 
Cixutumumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that selectively 
binds  to  membrane-bound  IGF-1R  (insulin  like  growth  factor-1  receptor)  thereby  preventing  the 
binding of the natural ligand IGF-1 (insulin-like growth factor).  The high affinity of cixutumumab  
(kd  =  10
−11  M)  is  sufficient  to  block  ligand  induced  receptor  activation.  IMC-A12  inhibited 
downstream  signaling  of  the  two  major  IGF  pathways,  mitogen-activated  protein  kinase  and 
phosphatidylinositol  3'-kinase/Akt,  but  does  not  block  the  insulin  receptor.  A  marked  increase  in 
apoptotic tumor cells was observed in in vivo tumor models [86]. Promising preclinical results with 
IMC-A12 suggested that it may be useful in effective therapeutic for a diverse array of oncologic 
indications [87]. There are 32 Phase I-II ongoing clinical trials employing cixutumumab. The first 
published  data  revealed  low  toxicity  and  moderate  effects.  In  the  phase  I/II  study  in  advanced  
non-small  cell  lung  cancer  (NSCLC),  cixutumumab  was  tolerated  as  a  single  agent  but  not  in 
combination with erlotinib; nevertheless, the efficacy in unselected patients with NSCLC seemed to be 
low [88]. A phase II study in patients with cetuximab or panitumumab-refractory metastatic colorectal 
cancer showed that IMC-A12 alone or in combination with cetuximab was insufficient to warrant 
additional  study  in  patients  with  colorectal  cancer  refractory  to  EGFR  inhibitors  [89].  Moreover, 
cixutumumab  was  well  tolerated  in  children  with  refractory  Ewing  sarcoma  and  a  phase  II  was 
recommended, even limited single-agent activity observation [90]. 
4.4. Necitumumab (IMC-11F8—ImClone Systems Incorporated) 
Necitumumab is a fully human IgG1 monoclonal antibody targeting the epidermal growth factor 
receptor (EGFR). Mutations that activate EGFR are present in diverse tumors including colorectal and 
non small-cell lung cancer (NSCLC). Several EGFR inhibitors like erlotinib and gefinitib are approved 
as anticancer agents in the US and Europe [91]. Necitumumab binds to the EGFR with high affinity 
(kd  =  0.32  nmol/L),  and  blocks  the  binding  of  EGFR  ligands,  neutralizing  ligand-induced  EGFR 
phosphorylation. As a consequence, necitumumab inhibits downstream targets in the EGFR pathway 
(e.g., MAPK) inhibiting proliferation of EGFR-dependent tumor cells. Moreover, it has the potential to Int. J. Mol. Sci. 2012, 13  5430 
 
induce  antibody-dependent  cell-mediated  cytotoxicity  against  tumor  cells  [92].  Preclinical  studies 
indicated that the antitumor activity of necitumumab is either comparable with or superior to that of 
Cetuximab, having the potential benefit of lower hypersensitivity reaction risk. There is two phase I 
clinical  trials in  solid tumors (NCT01088464, NCT00801177) and a  phase  II in  colorectal cancer 
combined  with  5-FU/FA  and  Oxaliplatin  ongoing  (NCT00835185).  Necitumumab  toxicity  is 
acceptable; with skin toxicity being the most frequently reported adverse event in the clinical trial 
studies  [93].  Recently,  a  Phase  III  study  of  necitumumab  combined  with  pemetrexed-cisplatin 
chemotherapy (INSPIRE) in patients with stage IV nonsquamous NSCLC was prematurely closed due 
to increased risk of thromboembolic events in the experimental arm [94]. Nevertheless, another Phase 
III  trial  of  necitumumab  in  combination  with  gemcitabine  and  cisplatin  in  squamous  NSCLC  is 
ongoing (NCT00981058). Success in this study will determine the clinical significance of this drug to 
future therapeutic strategies in NSCLC. 
4.5. Ramucirumab (IMC-1121B—ImClone Systems Incorporated) 
Ramucirumab (IMC-1121B) is a fully human IgG1 monoclonal antibody targeting the vascular 
endothelial  growth  factor  receptor-2  (VEGFR-2).  Similar  to  bevacizumab  (or  Avastin,  a  FDA 
approved  antibody),  which  directly  binds  to  and  neutralizes  circulating  VEGF  [95],  ramucirumab 
targets angiogenesis, an essential tumor-stroma interaction [96]. IMC-1121B’s unique mechanism of 
action  specifically  blocks  VEGFR-2  activation,  allowing  for  maximal  angiogenesis  inhibition. 
Ramucirumab is well tolerated, the most frequent related dose-limiting toxicities are hypertension and 
deep venous thrombosis, nausea, vomiting, headache, fatigue, and proteinuria were also noted [97]. 
Ramucirumab  is  under  evaluation  in  27  phase  I–III  clinical  trials  in  a  broad  array  of  cancers.  
A multinational randomized phase III trial will evaluate the efficacy and safety of ramucirumab, as 
standard first-line docetaxel chemotherapy for women with HER2-negative metastatic breast cancer by 
means of progression-free survival and overall survival [98]. Another Phase III study evaluating the 
safety and efficacy of ramucirumab as 2
nd-line treatment in patients with hepatocellular carcinoma 
after 1
st-line therapy with Sorafenib is under way (NCT01140347).  
4.6. Mapatumumab (HGS-ETR1—Human Genome Sciences Inc./GlaxoSmithKline) 
Mapatumumab (HGS-ETR1) is a human monoclonal antibody that specifically binds to TRAIL 
receptor-1 inducing cancer-cell death by apoptosis. TRAIL induces apoptosis through activation of 
death receptors TRAIL-R1 and TRAIL-R2. TRAIL receptor 1 is expressed on a variety of tumors. 
Mapatumumab has agonist activity and demonstrates tumor cell killing by apoptosis in vitro in a broad 
array of human cancer types and in preclinical animal models [99,100]. Mapatumumab was efficiently 
radiolabeled with  111In and can be used clinically to  study pharmacokinetics,  biodistribution  and 
tumor targeting, which could support evaluation of the native targeted agents in phase I/II trials [101]. 
Results from phase I and II studies have been reported and showed that Mapatumumab has potential 
either as a single agent or in combination with chemotherapy for the treatment of cancer. A phase Ib/II 
trial in patients with relapsed non-Hodgkin’s lymphoma (NHL) proved that mapatumumab is well 
tolerated, no patients experiencing drug-related hepatic or other dose-limiting toxicity. Results from 
three patients with follicular lymphoma (FL) showed a complete clinical response for two of them and Int. J. Mol. Sci. 2012, 13  5431 
 
a partial response in the third one. This places mapatumumab as a promising new therapeutic for 
patients  with  FL  [102].  In  a  Phase  II  clinical  trial  in  patients  with  refractory  colorectal  cancer 
Mapatumumab  showed  no  clinical  activity  as  single-agent,  however,  a  potential  synergy  in 
combination  with  agents  commonly  used  in  the  treatment  of  colorectal  cancer  warrants  further 
evaluation  [103].  A  phase  I  study  of  mapatumumab  in  combination  with  Nexavar  (sorafenib)  is 
currently underway in patients with advanced hepatocellular carcinoma (NCT00712855) and a Phase 
II study of mapatumumab in combination with bortezomib and bortezomib alone in subjects with 
relapsed or refractory multiple myeloma (MM) is ongoing (NCT00315757). 
4.7. Lexatumumab (HGS-ETR2—Human Genome Sciences Inc.) 
Lexatumumab  (HGS-ETR2)  is  a  fully  human  agonistic  mAb  that  targets  the  tumor  necrosis  
factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2). Lexatumumab activates the extrinsic 
apoptosis  pathway.  Upon  binding  to  TRAIL-R2,  HGS-ETR2  forms  a  death-inducing  signaling 
complex  with  the  adaptor  protein  FAS-associated  death  domain.  Following,  there  is  activation  of 
caspases 8 or 10, which then activate caspases 3, 6, and 7, resulting in apoptosis [104]. Lexatumumab 
showed potent preclinical antitumor activity mainly to solid tumors. A phase I study performed in 
37 patients with advanced solid tumors showed that lexatumumab was well tolerated and warrants 
additional evaluation, particularly in combination with chemotherapy agents [105]. In another phase I 
study, despite the observation that one patient experienced a possibly related dose-limiting toxicity of 
grade  3  hyperamylasemia,  they  concluded  that  lexatumumab  can  be  safely  administered.  Further 
evaluation of lexatumumab alone or in combination with other agents is suitable [106]. A phase I trial 
of lexatumumab with or without interferon gamma in patients with refractory pediatric solid tumors is 
underway (NCT00428272). 
4.8. Moxetumomab Pasudotox (HA22, CAT-8015, (RFB4(dsFv)-PE38—MedImmune) 
CAT-8015 is an anti-CD22 immunotoxin fusion protein between a murine anti-CD22 disulfide-linked 
Fv (dsFv) antibody fragment and a Pseudomonas exotoxin PE38. The original molecule CAT-3888 
(BL22), consisted of disulfide linked VH and VL chains of the mouse anti-CD22 monoclonal antibody 
RFB4 fused to a truncated form of ETA, PE38. RFB4 was originated from a mouse hybridoma [107] 
although phage display was employed to improve this molecule. CAT-8015 is a second-generation 
CD22 targeted immunotoxin. The PE38 portion of this construct is identical to that used for CAT-3888 
but the VH and VL chains have been affinity matured by phage display from a library targeting the 
CDR3 domain of the VH chain in a scFv format [108]. This procedure resulted in a variant containing 
three  amino  acids  changes  in  the  CDR3  that  increased  binding  affinity  for  the  target  molecule 
(approximately 14-fold, kd approximately 6 nM) when compared to the parental protein. The Fv binds 
to an antigen on a target cell and brings the toxin into the cell interior, where it arrests protein synthesis 
and initiates the apoptotic cascade [109]. CAT-8015 has greatly improved efficacy compared with 
CAT-3888 in preclinical studies using B-cell in vitro and in vivo tumor models [110]. There are 8 
phase  I/II  clinical  trials  using  CAT-8015  for  leukemia  or  lymphomas.  Recently  a  phase  I  
dose-escalation trial in chemotherapy-resistant hairy cell leukemia (HCL) was published. No dose-limiting 
toxicity was observed among the 28 patients enrolled [111]. Int. J. Mol. Sci. 2012, 13  5432 
 
5. Conclusions 
Combinatorial antibody phage display technologies provide robust means for the rapid discovery of 
tumor  antigen  antibodies  [13].  It  is  easy  to  implement  and  inexpensive.  Numerous  academic  and 
industrial laboratories have adopted the technique and contributed to its advancement. The methods for 
design, construction and screening of synthetic antibody libraries are constantly being improved and 
semi-automated selection strategies have been proposed. The advantage of antibody phage display is 
the  direct  isolation  of  fully  human  antibodies  in  comparison  to  antibodies  generated  by  mouse 
hybridoma technology where a laborious humanization procedure of the lead candidates is required. 
Many  products  of  phage  display  are  now  reaching  the  Biopharmaceutical  market.  Monoclonal 
antibodies had been the standard as anticancer agents by modulating intrinsic tumor cell pathways and 
activating the innate immune response against cancer cells. Phage display derived human antibodies 
obviously can compete with earlier generation products as long as they are directed to well defined 
targets such as the EGFR or VEGF pathway. Phage display plays an important role in drug discovery 
and development with a number of molecules approved by FDA and many others in clinical trials. It is 
normal to expect that greater improvement will be made in the near future and phage display will bring 
many more contributions to oncology. 
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